Improving Mental Health and Substance Use Disorder Care for the Nation

2021 ◽  
Vol 72 (7) ◽  
pp. 749-749
Author(s):  
Danielle S. Jackson ◽  
Whittney Wiley ◽  
Marcela Horvitz-Lennon
2008 ◽  
Vol 31 (1) ◽  
pp. 11-25 ◽  
Author(s):  
Roger G. Kathol ◽  
Steve Melek ◽  
Byron Bair ◽  
Susan Sargent

2003 ◽  
Vol 37 (3) ◽  
pp. 286-293 ◽  
Author(s):  
Gregory L. Carter ◽  
Cathy Issakidis ◽  
Kerrie Clover

Objective: This study (i) explores differences between a clinical sample of deliberate selfpoisoning (DSP) patients and a community sample who reported previous attempted suicide (AS); and (ii) examines correlates of suicidal behaviour in these groups compared with a community control group (CC) with no suicidal behaviour. Method: The study design was: case–case, case–control and cross-sectional population studies. A clinical sample of DSP (n = 51), a community sample of AS (n = 31) and a community sample with no suicidal behaviour (n = 842) were used, all aged 18–24 years. The DSP and AS groups were compared on several variables and two logistic regression models were developed for risk of (i) DSP and (ii) AS compared to community controls. Results: The adjusted odds ratios for DSP were: female gender (OR = 5.7, CI = 1.7–19.4), anxiety (OR = 7.4, CI = 2.2–25.1), affective (OR = 23.0, CI = 6.9–76.5), or substance-use disorder (OR = 19.2, CI = 5.6–65.4) and greater mental health related disability (OR = 0.5, CI = 0.3–0.7 for 1 SD decrease). For AS the results were: anxiety (OR = 9.4, CI = 1.7–52.8) or substance-use disorder (OR = 3.0, CI = 1.1–8.7) and greater mental health disability (OR = 0.5, CI = 0.4–0.7). Affective disorder was close to significant for the AS group (OR = 4.0, CI = 0.9–17.1). Conclusions: Correlates of DSP/AS were usually more powerful in the clinical group, but showed a similar pattern of psychiatric disorder and disability factors in both groups, supporting a continuum of risk factors across these groups. Interventions based on modifiable risk factors could target the same factors for public health, primary care or hospital populations: anxiety, depression and substance use disorders and mental health related disability.


2017 ◽  
Vol 66 (2) ◽  
pp. 120-123 ◽  
Author(s):  
Julio Mario Xerfan do Amaral ◽  
Marcelo Santos Cruz

ABSTRACT The present study reports several case studies about the use of androgenic-anabolic steroids (AAS) by patients under treatment for substance use disorder (SUD). Ten subjects were interviewed, two women and eight men, ranging from 25 to 43 years old. Regarding treatment regime, eight subjects were inpatients and two, outpatients. ASSIST-WHO and MINI-SUD scales and a semi-structured interview were used as research instruments. Seven subjects reported the use of AAS within fewer than twelve months from the interview date. Mental health professionals did not previously question none of the subjects were about the use of AAS. We discuss the efficacy of the chosen instruments to assess AAS use.


2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Inmaculada Guerrero Fernández de Alba ◽  
Antonio Gimeno-Miguel ◽  
Beatriz Poblador-Plou ◽  
Luis Andrés Gimeno-Feliu ◽  
Ignatios Ioakeim-Skoufa ◽  
...  

Abstract Type 2 diabetes mellitus (T2D) is often accompanied by chronic diseases, including mental health problems. We aimed at studying mental health comorbidity prevalence in T2D patients and its association with T2D outcomes through a retrospective, observational study of individuals of the EpiChron Cohort (Aragón, Spain) with prevalent T2D in 2011 (n = 63,365). Participants were categorized as having or not mental health comorbidity (i.e., depression, anxiety, schizophrenia, and/or substance use disorder). We performed logistic regression models, controlled for age, sex and comorbidities, to analyse the likelihood of 4-year mortality, 1-year all-cause hospitalization, T2D-hospitalization, and emergency room visit. Mental health comorbidity was observed in 19% of patients. Depression was the most frequent condition, especially in women (20.7% vs. 7.57%). Mortality risk was higher in patients with mental health comorbidity (odds ratio 1.24; 95% confidence interval 1.16–1.31), especially in those with substance use disorder (2.18; 1.84–2.57) and schizophrenia (1.82; 1.50–2.21). Mental health comorbidity also increased the likelihood of all-cause hospitalization (1.16; 1.10–1.23), T2D-hospitalization (1.51; 1.18–1.93) and emergency room visit (1.26; 1.21–1.32). These results suggest that T2D healthcare management should include specific strategies for the early detection and treatment of mental health problems to reduce its impact on health outcomes.


Addiction ◽  
2019 ◽  
Vol 114 (8) ◽  
pp. 1446-1459 ◽  
Author(s):  
Meredith G. Harris ◽  
Chrianna Bharat ◽  
Meyer D. Glantz ◽  
Nancy A. Sampson ◽  
Ali Al‐Hamzawi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document